Magnetic Resonance Spectroscopy in Glioma Metabolism

Magnetic resonance spectroscopy (MRS) has emerged as a pivotal non-invasive technique for characterising the biochemical landscape of gliomas. By resolving individual metabolite resonances in vivo, MRS probes tumour energy pathways, membrane turnover and oncometabolite accumulation, providing insights into genetic subtypes, malignancy grade and treatment response. Central to glioma metabolism is the mutant isocitrate dehydrogenase (IDH) pathway, which produces the oncometabolite 2-hydroxyglutarate (2HG) and alters glutamine, glutamate and phospholipid homeostasis. Advances in hardware, such as ultrahigh field magnets and hyperpolarisation of stable isotopes, have substantially improved spectral resolution and sensitivity, enabling dynamic flux measurements in single voxels or multi-voxel arrays. Clinically, MRS complements anatomical MRI by refining diagnosis, monitoring targeted therapies and predicting outcome. Ongoing developments aim to standardise acquisition protocols, reduce artefacts and integrate metabolic maps with other molecular imaging modalities for precision management of glioma patients.

Research from Nature Portfolio

Hyperpolarised 13C δ-gluconolactone MRS has been used to monitor flux through the pentose phosphate pathway in glioblastoma models with mutant TERT promoters. Silencing of TERT or its cofactor GABPB1 produced marked reductions in downstream 6-phosphogluconolactone signals in live cells and orthotopic tumours, demonstrating the potential of this approach to assess target engagement in real time. In a foundational clinical study of mutant IDH1 inhibitors, three-dimensional 2HG imaging by volumetric MRS identified rapid pharmacodynamic responses in patients, with a substantial decrease in tumour 2HG levels after one week of treatment. This work established non-invasive MRS as a viable radiopharmacodynamic tool for early assessment of targeted therapies in glioma.

Magnetic Resonance Spectroscopy in Glioma Metabolism publication trend

The graph below shows the total number of articles in magnetic resonance spectroscopy in glioma metabolism across all publications each year (not limited to Nature Index journals).

Technical terms

Magnetic resonance spectroscopy (MRS): A non-invasive imaging technique that quantifies tissue metabolites by detecting chemical shift differences in the magnetic resonance signal.

2-Hydroxyglutarate (2HG): An oncometabolite produced by mutant IDH enzymes, serving as a biomarker for IDH-mutant gliomas.

Hyperpolarisation: A method to transiently increase signal strength of 13C-labelled substrates, enabling real-time tracking of metabolic fluxes.

Isocitrate dehydrogenase (IDH): An enzyme implicated in cellular metabolism; its oncogenic mutations reprogramme energy pathways in gliomas.

Single-voxel spectroscopy (SVS): An MRS acquisition that targets a defined three-dimensional volume for metabolite quantification.

Multi-voxel spectroscopy (MRSI): An imaging variant that generates spatially resolved metabolic maps over a two- or three-dimensional grid.

Signal-to-noise ratio (SNR): A measure of spectral quality reflecting the relative strength of metabolite signals to background noise.

Cramér-Rao lower bound (CRLB): A statistical estimate of the minimum variance of metabolite quantification, used to assess spectral reliability.

References

1. Hyperpolarized δ-[1- 13C]gluconolactone imaging visualizes response to TERT or GABPB1 targeting therapy for glioblastoma. Scientific Reports (2023).
2. Pharmacodynamics of mutant-IDH1 inhibitors in glioma patients probed by in vivo 3D MRS imaging of 2-hydroxyglutarate. Nature Communications (2018).
3. Non-Invasive Assessment of Isocitrate Dehydrogenase-Mutant Gliomas Using Optimized Proton Magnetic Resonance Spectroscopy on a Routine Clinical 3-Tesla MRI. Cancers (2023).
4. Single-Voxel MR Spectroscopy of Gliomas with s-LASER at 7T. Diagnostics (2023).
5. Monitoring response to a clinically relevant IDH inhibitor in glioma—Hyperpolarized 13C magnetic resonance spectroscopy approaches. Neuro-Oncology Advances (2023).